Adam Walsh

Stock Analyst at Roth Capital

(2.71)
# 2,351
Out of 5,182 analysts
18
Total ratings
62.5%
Success rate
18.98%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Adam Walsh

Equillium
Apr 17, 2026
Reiterates: Buy
Price Target: $12
Current: $2.05
Upside: +485.37%
Insmed
Apr 17, 2026
Reiterates: Buy
Price Target: $212
Current: $134.94
Upside: +57.11%
Apellis Pharmaceuticals
Mar 13, 2026
Initiates: Buy
Price Target: $31
Current: $40.99
Upside: -24.37%
vTv Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $58
Current: $31.97
Upside: +81.42%
Ascendis Pharma
Apr 20, 2020
Maintains: Buy
Price Target: $146$171
Current: $222.08
Upside: -23.00%
Galapagos NV
Jul 15, 2019
Maintains: Buy
Price Target: $121$188
Current: $28.43
Upside: +561.27%
Corcept Therapeutics
May 31, 2018
Downgrades: Hold
Price Target: n/a
Current: $46.62
Upside: -
Ultragenyx Pharmaceutical
Apr 18, 2018
Maintains: Buy
Price Target: $74$77
Current: $24.53
Upside: +213.90%